Galena Biopharma (NASDAQ:GALE) has climbed 6.73% in the past week and advanced 46.05% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 8.01% and the outperformance has advanced to 44.72% for the last 4 weeks period.
Galena Biopharma (NASDAQ:GALE): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.15 and $2.14 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.30. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.22, notching a gain of 3.26% for the day. The total traded volume was 4,749,907 . The stock had closed at $2.15 on the previous day.
The company shares have rallied 21.98% from its 1 Year high price. On Jun 17, 2016, the shares registered one year high at $2.30 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $1.68 and the 200 Day Moving Average price is recorded at $1.27.
On the companys insider trading activities, The officer (Former Chief Financial Officer), of Galena Biopharma, Inc., Dunlap Ryan had unloaded 126,875 shares at $2.18 per share in a transaction on June 1, 2016. The total value of transaction was $276,588. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Roth Capital maintains their rating on the shares of Galena Biopharma (NASDAQ:GALE). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $5 per share from $6 per share. The rating by the firm was issued on March 11, 2016. Currently the company Insiders own 2.96% of Galena Biopharma shares according to the proxy statements. Institutional Investors own 15.46% of Galena Biopharma shares.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.